BGI
Researchers narrowed in on dual-treatment targets using expression and regulatory programs found in glioblastoma cells in and around the tumor.
BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China
Premium
The molecular residual disease test from Natera was first made available to biopharmaceutical customers and clinicians across China in June.
Maternal Cancer Detection From Noninvasive Prenatal Screening Results Improved by Algorithm
A Chinese study involving NIPS data from almost two million pregnant women found that a new bioinformatic approach improves the detection of cancer.
Natera, BGI Genomics Ink $50M Deal to Develop, Launch Liquid Biopsy Tests in China, Elsewhere
Using BGI's sequencing technology, the firms plan to commercialize Natera's Signatera test in China and to develop reproductive health tests in "select markets."